JP2021527049A5 - - Google Patents

Info

Publication number
JP2021527049A5
JP2021527049A5 JP2020567815A JP2020567815A JP2021527049A5 JP 2021527049 A5 JP2021527049 A5 JP 2021527049A5 JP 2020567815 A JP2020567815 A JP 2020567815A JP 2020567815 A JP2020567815 A JP 2020567815A JP 2021527049 A5 JP2021527049 A5 JP 2021527049A5
Authority
JP
Japan
Prior art keywords
compound
composition according
mitochondrial
deficiency
composition
Prior art date
Application number
JP2020567815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527049A (ja
JP7376934B2 (ja
JPWO2019234664A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054696 external-priority patent/WO2019234664A1/en
Publication of JP2021527049A publication Critical patent/JP2021527049A/ja
Publication of JP2021527049A5 publication Critical patent/JP2021527049A5/ja
Publication of JPWO2019234664A5 publication Critical patent/JPWO2019234664A5/ja
Application granted granted Critical
Publication of JP7376934B2 publication Critical patent/JP7376934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567815A 2018-06-06 2019-06-06 ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩 Active JP7376934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
EP18382397.0 2018-06-06
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (4)

Publication Number Publication Date
JP2021527049A JP2021527049A (ja) 2021-10-11
JP2021527049A5 true JP2021527049A5 (https=) 2022-06-14
JPWO2019234664A5 JPWO2019234664A5 (https=) 2022-06-14
JP7376934B2 JP7376934B2 (ja) 2023-11-09

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567815A Active JP7376934B2 (ja) 2018-06-06 2019-06-06 ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩

Country Status (13)

Country Link
US (2) US11957670B2 (https=)
EP (2) EP4545142A3 (https=)
JP (1) JP7376934B2 (https=)
DK (1) DK3801515T3 (https=)
ES (1) ES3028538T3 (https=)
FI (1) FI3801515T3 (https=)
HR (1) HRP20250591T1 (https=)
HU (1) HUE071482T2 (https=)
LT (1) LT3801515T (https=)
PL (1) PL3801515T3 (https=)
PT (1) PT3801515T (https=)
SI (1) SI3801515T1 (https=)
WO (1) WO2019234664A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3917508A4 (en) 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
CA3127453A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EP3125888B1 (en) 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017057587A1 (ja) 2015-09-30 2017-04-06 株式会社ニコン 露光装置、フラットパネルディスプレイの製造方法、及びデバイス製造方法
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
EP3548026B1 (en) 2016-12-01 2021-01-20 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EA202092954A1 (ru) 2018-06-06 2021-04-08 Минорикс Терапьютикс С.Л. Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
BR112020024917A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona

Similar Documents

Publication Publication Date Title
JP2021527049A5 (https=)
JP2021527061A5 (https=)
EP3600318A1 (en) Methods of using ehmt2 inhibitors
BR102018004952A2 (pt) composição farmacêutica, e, método para tratar uma doença ou distúrbio mediado por jak
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
AU2009321722B2 (en) Methods for preventing or reducing colon carcinogenesis
WO2008063842A2 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
JP2021527045A5 (https=)
JP7510170B2 (ja) ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
MX2013005561A (es) Metodo para tratar enfermedades de los ojos asociadas con inflamacion o proliferacion vascular.
US7846968B2 (en) Methods for QT interval control
JPWO2019234664A5 (https=)
EP3782648B1 (en) Prostaglandin d2 production inhibitors as preventative and therapeutic agents for sarcopenia
US6632838B1 (en) Use of bissulfonamides for producing medicines for the treatment of hyperlipidemia
DK2882708T3 (en) NEW CONNECTIONS AND APPLICATIONS THEREOF
US20150210679A1 (en) Small molecule inhibitors of superoxide dismutase expression
BG63367B1 (bg) Нитробензамиди, полезни като противоаритмични средства
KR20210129034A (ko) 치환된 융합 이미다졸 유도체 및 겸상 적혈구 질환과 관련 합병증을 치료하는 방법
JPWO2020014504A5 (https=)
CN101507726B (zh) 窦房结If电流抑制剂和β-阻滞剂的组合
JP7570108B2 (ja) ミトコンドリア病の治療における使用のためのカンナビジオールおよび／またはその誘導体
EP3377476B1 (en) Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
BR112014017272B1 (pt) composto éster de ácido acético ou sal do mesmo, composição farmacêutica, agente terapêutico e/ou profilático e uso do referido composto
CN102731400A (zh) 一种盐酸伊伐布雷定的新晶型、制备方法及其在制备药物组合物中的用途